Advertisement
Screener

LB Pharmaceuticals Inc (LBRX) Graph

LBRX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $44.15M; Operating expenses $53.91M; Income tax $0.00; Net income -$51.60M.
  • 2026-03-31: Research and development $14.64M; Operating expenses $22.10M; Income tax $0.00; Net income -$19.05M.
  • 2025-12-31: Research and development $8.48M*; Operating expenses $13.87M*; Income tax $1.00K*; Net income -$11.47M*.
  • 2025-09-30: Research and development $2.42M; Operating expenses $5.25M; Income tax $0.00; Net income -$3.56M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$44.15M$53.91M$0.00-$51.60M
2026-03-31$14.64M$22.10M$0.00-$19.05M
2025-12-31$8.48M*$13.87M*$1.00K*-$11.47M*
2025-09-30$2.42M$5.25M$0.00-$3.56M
2025-06-30$2.42M$4.86M$0.00-$4.87M
2025-03-31$3.42M$6.43M$0.00-$5.31M
2024-09-30$10.66M$16.08M$0.00-$14.18M
2024-06-30(m)(m)(m)-$27.63M
2024-03-31(m)(m)(m)-$16.22M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$58.79M$76.02M$0.00-$70.66M
2025-06-30$5.84M$11.29M$0.00-$10.18M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$8.26M$16.53M$0.00-$13.73M
2024-09-30$50.80M$59.29M$0.00-$58.03M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$16.74M$30.40M$1.00K-$25.20M
2024-12-31$51.17M$64.83M$1.00K-$63.10M

Similar stocks

Stock NameCountryMarket CapPE Ratio
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
HARROW, INC. (HROW)United States$1.240B-42.77
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93